Clinical and experimental nephrology · 2025
Serum matrix metalloproteinase-9 as a predictor of recurrence in idiopathic nephrotic syndrome.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ochi Masahiko, Hara Akinori, Nakagawa Shiori, Oshima Megumi, Kitajima Shinji, Toyama Tadashi, Sakai Norihiko, Shimizu Miho, Iwata Yasunori, Wada Takashi
Аннотация
BACKGROUND: The risk factors for the recurrence of idiopathic nephrotic syndrome (INS) remain unknown. Previous studies have suggested a potential link between matrix metalloproteinase-9 (MMP-9) and urinary protein levels in INS. Therefore, we aimed to investigate the association between serum MMP-9 levels and the risk of subsequent recurrence in patients with INS.
METHODS: This retrospective study included 29 patients with biopsy-proven INS from 1998 to 2016. Baseline serum MMP-9 levels during the nephrotic phase were measured using an enzyme-linked immunosorbent assay. Subsequent recurrence was defined as a change in urinary protein levels from remission to more than 2 + on a dipstick test or more than 1 g/g creatinine.
RESULTS: The median age was 42 years (interquartile range: 26.0, 70.0), and 18 patients were males. Over a median follow-up period of 130 days, 12 patients (41.4%) experienced recurrences. Patients who experienced recurrence were younger and had higher estimated glomerular filtration rates and baseline serum MMP-9 levels during the nephrotic phase than those who did not. Higher baseline serum MMP-9 levels during the nephrotic phase were associated with a higher risk of subsequent recurrence (hazard ratio: 5.687, 95% confidence interval: 1.179-27.44).
CONCLUSION: Baseline serum MMP-9 levels during the nephrotic phase were associated with subsequent recurrence in patients with INS, indicating its potential as a predictive marker for future recurrence in patients with INS.
METHODS: This retrospective study included 29 patients with biopsy-proven INS from 1998 to 2016. Baseline serum MMP-9 levels during the nephrotic phase were measured using an enzyme-linked immunosorbent assay. Subsequent recurrence was defined as a change in urinary protein levels from remission to more than 2 + on a dipstick test or more than 1 g/g creatinine.
RESULTS: The median age was 42 years (interquartile range: 26.0, 70.0), and 18 patients were males. Over a median follow-up period of 130 days, 12 patients (41.4%) experienced recurrences. Patients who experienced recurrence were younger and had higher estimated glomerular filtration rates and baseline serum MMP-9 levels during the nephrotic phase than those who did not. Higher baseline serum MMP-9 levels during the nephrotic phase were associated with a higher risk of subsequent recurrence (hazard ratio: 5.687, 95% confidence interval: 1.179-27.44).
CONCLUSION: Baseline serum MMP-9 levels during the nephrotic phase were associated with subsequent recurrence in patients with INS, indicating its potential as a predictive marker for future recurrence in patients with INS.